Peter W Glunz

USPTO Granted Patents = 28 (Patent Applications = 2)

EPO Patents = 15 (Patent Applications = 16)

Average Co-Inventor Count = 4.2

ph-index = 6

Forward Citations = 146(Granted Patents)

Location History:

Wilmingtonq, DE (US) (2006)
Wilmington, DE (US) (2003 - 2007)
Yardley, PA (US) (2006 - 2023)

Company Filing History:

24 out of 3,681

Bristol-myers Squibb Compnay

patents

3 out of 512

Sloan-kettering Institute for Cancer Research

patents

1 out of 234

Bristol-myers Squibb Pharma Company

patents

Years Active: 2003-2023

Loading Chart...

28 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11673886 - 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK (2023-06-13),

2. 11078197 - 5-membered and bicyclic heterocyclic amides as inhibitors of rock (2021-08-03),

3. 10829501 - Spiroheptane salicylamides and related compounds as inhibitors of ROCK (2020-11-10),

4. 10787450 - Spiro-fused cyclic ureas as inhibitors of rock (2020-09-29),

5. 10730858 - Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors (2020-08-04),

6. 10696674 - Spirolactams as inhibitors of ROCK (2020-06-30),

7. 10654860 - Tricyclic rho kinase inhibitors (2020-05-19),

8. 10611776 - Spiroheptane salicylamides and related compounds as inhibitors of rock (2020-04-07),

9. 10562887 - Triazolones and tetrazolones as inhibitors of ROCK (2020-02-18),

10. 10385026 - Phthalazinones and isoquinolinones as rock inhibitors (2019-08-20),

11. 10123993 - Cyclic ureas as inhibitors of rock (2018-11-13),

12. 10112929 - Lactams as inhibitors of rock (2018-10-30),

13. 9926282 - Phthalazinones and isoquinolinones as rock inhibitors (2018-03-27),

14. 9902702 - Spirocycloheptanes as inhibitors of rock (2018-02-27),

15. 9458110 - Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors (2016-10-04),

Title: The Innovative Journey of Inventor Peter W Glunz

Introduction: Peter W Glunz, a prolific inventor based in Yardley, PA (US), has made significant contributions to the field of pharmaceuticals with a total of 28 patents under his belt. His dedication to innovation has paved the way for groundbreaking advancements in medicine.

Latest Patents: Among his latest patented inventions are 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK. These compounds have shown great promise as selective ROCK inhibitors, with implications for treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and inflammatory disorders. The pharmaceutical compositions derived from his inventions have the potential to revolutionize the treatment of a wide range of medical conditions.

Career Highlights: Peter W Glunz has been associated with prominent companies such as Bristol-Myers Squibb Company and the Sloan-Kettering Institute for Cancer Research. His professional journey has been marked by a relentless pursuit of excellence and a commitment to pushing the boundaries of scientific discovery.

Collaborations: Throughout his career, Peter W Glunz has collaborated with esteemed professionals in the field, including coworkers like Vladimir Ladziata and Mimi Lifen Quan. These collaborative efforts have led to the development of innovative solutions that have the power to transform the landscape of modern medicine.

Conclusion: Peter W Glunz stands as a beacon of inspiration for inventors worldwide, showcasing the transformative impact of unwavering dedication to innovation. His pioneering work continues to shape the future of medicine, offering hope and possibilities for patients and researchers alike.

This text is generated by artificial intelligence and may not be accurate.